JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2007; 49:1035-1042, doi:10.1016/j.jacc.2006.10.064 (Published online 23 February 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piorkowski, M.
Right arrow Articles by Rauch, U.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Piorkowski, M.
Right arrow Articles by Rauch, U.

Treatment With Ezetimibe Plus Low-Dose Atorvastatin Compared With Higher-Dose Atorvastatin Alone

Is Sufficient Cholesterol-Lowering Enough to Inhibit Platelets?

Michael Piorkowski, MD*, Sabine Fischer, MD*, Caroline Stellbaum, MD*, Markus Jaster, MD*, Peter Martus, PhD{dagger}, Andreas J. Morguet, MD*, Heinz-Peter Schultheiss, MD* and Ursula Rauch, MD*,*

* Department of Internal Medicine/Cardiology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Berlin, Germany
{dagger} Institute for Biostatistics and Clinical Epidemiology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Berlin, Germany.


Figure 1
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1 Differences in Low-Density Lipoprotein Cholesterol Levels ({Delta}LDL-C)

Levels at 4 weeks after lipid-lowering therapy compared with levels before changing treatment. Atorvastatin 40 mg/day (open bars, n = 25) and ezetimibe 10 mg/day plus atorvastatin 10 mg/day (solid bars, n = 26).

 

Figure 2
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2 Differences in ADP-Induced P-Selectin Expression on Platelets

(A) Platelet P-selectin expression after adenosine diphosphate (ADP) stimulation at baseline and after 4 weeks of lipid-lowering therapy with atorvastatin (open bars, n = 25) or a combination of ezetimibe plus atorvastatin (solid bars, n = 26). (B) Differences in median immunofluorescence intensity ({Delta}MFI) in P-selectin expression (level after 4 weeks of lipid-lowering therapy minus level before changing treatment). AU = arbitrary units.

 

Figure 3
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3 Differences in TRAP-Induced P-Selectin Expression on Platelets

(A) Platelet P-selectin expression after stimulation with thrombin receptor-activating peptide (TRAP) at baseline and after 4 weeks of lipid-lowering therapy with atorvastatin (open bars, n = 25) or a combination of ezetimibe plus atorvastatin (solid bars, n = 26). (B) Differences in median immunofluorescence intensity in P-selectin expression (level after 4 weeks of lipid-lowering therapy minus level before changing treatment). Abbreviations as in Figure 2.

 

Figure 4
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4 RANTES Levels in Blood Pre- and Post–Lipid-Lowering Therapy

(A) Plasma regulated on activation normally T-cell expressed and secreted (RANTES) concentration at baseline and after 4 weeks of lipid-lowering therapy with atorvastatin (open bars, n = 25) or a combination of ezetimibe plus atorvastatin (solid bars, n = 26). (B) Differences ({Delta}c) in plasma RANTES concentration (level after 4 weeks of lipid-lowering therapy minus level before changing treatment). c = concentration.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2007 by the American College of Cardiology Foundation.